Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing precision medicines for rare neuroendocrine diseases characterized by hyperphagia and severe obesity. The company's lead product, IMCIVREE (setmelanotide), is a melanocortin-4 receptor (MC4R) agonist approved in the United States, European Union, United Kingdom, Canada, and Japan for the treatment of obesity associated with Bardet-Biedl syndrome, pro-opiomelanocortin (POMC) deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, and leptin receptor (LEPR) deficiency. Regulatory approvals for IMCIVREE in acquired hypothalamic obesity are pending in the United States and Europe, with additional submissions in progress in Japan. The company is also advancing two investigational MC4R agonists, bivamelagon (an oral small molecule) and RM-718 (a subcutaneous formulation), which are designed to treat hypothalamic obesity and Prader-Willi syndrome without inducing hyperpigmentation. Rhythm maintains a global clinical trial program and utilizes a large DNA database to identify patients with genetically defined MC4R pathway deficiencies. The company serves patients and healthcare providers in North America, Europe, and Asia, offering disease awareness resources and patient support programs.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage rhythmtx.com
Sector Healthcare IR page ir.rhythmtx.com/news
Tags
rare diseases, neuroendocrine disorders, obesity treatment, mc4r agonists, hyperphagia, genetic testing, precision medicine, bardet-biedl syndrome, hypothalamic obesity, prader-willi syndrome, IMCIVREE, setmelanotide, bivamelagon, RM-718, LB54640, Rhythm InTune
Press page —

Metrics

Valuation  
Market cap $ 7.666B
Market cap (USD) $ 7.666B
P/E -38.14
PEG —
P/BV 87.15
P/S 27.31
P/OCF -93.74
P/FCF -65.73
Dividend yield —
Turnover / mcap —
Returns  
ROE -244.5%
ROI -79.5%
ROIC -58.2%
Profit margin -103.6%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 116.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 106
Quality score -41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Revenue 189.757M 130.126M 77.428M 23.638M 3.154M 0 0 0 0 0
Net profit -196.539M -260.602M -184.678M -181.119M -69.612M -133.996M -140.729M -74.064M -33.709M -25.872M
Free cash flow -116.628M -113.879M -136.204M -173.709M -146.437M -122.194M -126.135M -62.778M -29.593M -24.276M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Share price 107.04 55.98 45.97 29.12 9.98 29.73 22.96 26.88 29.06 —
Price performance 12m 0.91 0.22 0.58 1.92 -0.66 0.29 -0.15 -0.08 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — 1.03M 6.22M 14.9M 18.5M 26.1M
↳ YoY growth +507.2% +138.9% +24.5% +40.9%
Borrowings, current (USD) — — — — — — — — 1.54M 7.3M
Borrowings, non-current (USD) — — — — — — — 106M 108M 101M
Lease liabilities (USD) — — 3.64M 3.56M 3.09M 2.55M 1.94M 1.26M 3.94M 3.99M
Cash and deposits (USD) 6.54M 34.2M 49.5M 62.3M 101M 59.2M 128M 60.1M 89.1M 54.3M
Intangible assets (USD) — — — — — 4.66M 7.88M 7.03M 6.17M 5.32M
Right-of-use assets (USD) — — 3.27M 2.05M 1.81M 1.52M 1.18M 781,000 3.48M 3.05M
Net debt (borrowings + leases - cash) (USD) — — — — — — — 47.3M 24.6M 57.9M
Cash flow detail
Operating cash flow (USD) -23.2M -29.5M -62.1M -123M -122M -146M -173M -136M -114M -116M
Purchases of property, plant and equipment (USD) -1.06M -133,000 -722,000 -3.39M -214,000 -434,000 -281,000 -47,000 0.00 -953,000
Purchases of intangible assets (USD) — — — — — — — -5.67M -40.5M -40M
Change in receivables (cash effect) (USD) — — — — — -1.25M -5.2M -8.64M -3.65M -7.57M
Change in inventories (cash effect) (USD) — — — — — -11,000 -2.81M -5.71M -10.1M -7.47M
Change in payables (cash effect) (USD) 160,000 1.95M 6.95M 10.5M -6.45M 18.3M 1.54M 14.8M 21.9M 21.9M
Share-based compensation (USD) 1.17M 2.28M 6.39M 11.9M 17.5M 20.8M 19.8M 32.6M 39.7M 66.8M
Operating cash flow before change in receivables (USD) — — — — — -145M -168M -128M -110M -108M
Free cash flow (OCF - PPE - intangibles) (USD) -24.3M -29.6M -62.8M -126M -122M -146M -174M -142M -154M -157M
Income detail
Research and development expense (USD) 19.6M 22.9M 50.3M 109M 90.5M 104M 109M 135M 238M 167M
↳ 5y CAGR +66.1% +39.7% +36.5% +21.8% +16.8% +13.1%
Total comprehensive income (USD) — — -74.1M -141M -134M -69.6M -181M -184M -265M -203M
Comprehensive income to owners (USD) — — -74.1M -141M -134M -69.6M -181M -184M -265M -203M
Provision for credit losses (USD) — — — — — 569,000 3.67M 19M 29.6M 49.5M
Credit cost ratio (credit losses / average receivables) (%) — — — — — — 101.1% 180.4% 177.5% 221.9%
Reported Mar 12, 2018 Mar 12, 2018 Mar 1, 2021 Mar 1, 2021 Mar 1, 2021 Mar 1, 2023 Mar 1, 2023 Feb 28, 2025 Feb 26, 2026 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 4, 2026

PDF Version

-- Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome --

BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the National Institute for Health and Care Excellence (NICE) has issued a positive guidance for IMCIVREE® (setmelanotide) to include adults living with genetically confirmed Bardet-Biedl syndrome (BBS).

The expansion of reimbursement eligibility by NICE allows adults living with BBS to access funded treatment through the National Health Service (NHS). The updated guidance expands NICE's previous recommendation for setmelanotide in BBS from May 2024, which had optimized treatment initiation for patients ages 6 to 17 years. NICE considered additional clinical, real-world and disease burden evidence, including longer-term treatment data, and recognized the significant burden that hyperphagia and obesity associated with BBS can have on patients and families. This assessment reflects the broad impact of BBS on quality of life, mental health, mobility, education and independence.

"This updated recommendation is welcome news for adults in England, Wales and Northern Ireland living with Bardet-Biedl syndrome," said Professor Philip Beales, Emeritus Professor of Molecular Genetics and Genomic Medicine at University College London. "BBS is a lifelong disease, and adults continue to experience the significant burden of hyperphagia and obesity throughout their lives. Expanding access to setmelanotide means more people living with BBS will have the opportunity to receive treatment.”

Setmelanotide for children between the ages of two to five years old in England and Wales with BBS is funded through NHS England specialized commissioning arrangements. The updated NICE guidance does not change existing access arrangements for this group.

This press release is intended for investors only.

About Rhythm Pharmaceuticals Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 4 years and older with acquired hypothalamic obesity, adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and control of hunger in patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment; and for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.

Setmelanotide Indication In the United States, setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity, in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).

In the European Union and the United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above, and for the treatment of obesity and control of hunger in adults and children 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment. In the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician experienced in the diagnosis and management of rare forms of obesity with genetic or hypothalamic origin.

The European Union summary of product characteristics can be accessed by clinking this LINK.

The United Kingdom summary of product characteristics can be access by clicking this LINK.

Information for audiences in the Unites States of America

Limitations of Use

Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:

  • Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign

  • Other types of obesity not related to acquired HO, BBS, or POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity.

Important Safety Information

CONTRAINDICATIONS

Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.

WARNINGS AND PRECAUTIONS

**Disturbance in Sexual Arousal:**Spontaneous penile erections and increased frequency of penile erections in males have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.

**Depression and Suicidal Ideation:**Depression and suicidal ideation have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.

**Hypersensitivity Reactions:**Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.

**Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New Melanocytic Nevi:**Generalized or focal increases in skin pigmentation occurred in the majority of IMCIVREE-treated patients. IMCIVREE may also cause development of new melanocytic nevi or darkening of pre-existing nevi. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions.

**Acute Adrenal Insufficiency with Acquired HO:**Patients with acquired HO and secondary adrenal insufficiency reported serious adverse reactions related to acute adrenal insufficiency in 5% of IMCIVREE-treated patients and no placebo-treated patients. In patients with secondary adrenal insufficiency, monitor for clinical signs of acute adrenal insufficiency.

Sodium Imbalance in Patients with Acquired HO and Central Diabetes Insipidus: Patients with acquired HO and concomitant central diabetes insipidus (DI)/arginine vasopressin (AVP) deficiency reported hyponatremia in 6% of IMCIVREE-treated patients and 2% of placebo-treated patients and hypernatremia in 5% of IMCIVREE-treated patients and 4% of placebo-treated patients. Monitor serum sodium levels with changes in fluid intake and hydration status. Adjust the doses of concomitant therapies for DI/AVP deficiency as needed.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥20% in at least 1 indication) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection.

USE IN SPECIFIC POPULATIONS

Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.

To report suspected adverse reactions in the United States, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

By reporting side effects, you can help provide more information on the safety of this medicine

Please see the full Prescribing Information for additional Important Safety Information.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the safety, efficacy, potential benefits of, and clinical design or progress of any of our products or product candidates at any dosage or in any indication, including, the impact of certain regulatory approvals of IMCIVREE for the treatment of BBS in England, Wales and Northern Ireland and expectations surrounding coverage and availability of IMCIVREE; and the timing of any of the foregoing. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, risks associated with the laws and regulations governing our international operations and the costs of any related compliance programs, our ability to successfully commercialize setmelanotide, our liquidity and expenses, our ability to retain our key employees and consultants, and to attract, retain and motivate qualified personnel, and general economic conditions, and the other important factors, including those discussed under the caption “Risk Factors” in Rhythm’s Quarterly Report on Form 10-Q for the three months ended June 30, 2026, and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Corporate Contacts: David Connolly Head of Investor Relations and Corporate Communications Rhythm Pharmaceuticals, Inc. 857-264-4280 [email protected]

Kate Walsh Director, Corporate Communications Rhythm Pharmaceuticals, Inc. (857) 264-4280 [email protected]

Primary Logo

November 3, 2026

PDF Version

-- Strong U.S. launch momentum for IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 --

-- Third quarter 2026 net product revenue from global sales of IMCIVREE of $92.1 million, an increase of 29% from the prior quarter --

-- Commercial launch of IMCIVREE in Japan for patients with acquired HO underway --

-- Bivamelagon to advance into pivotal development in Prader-Willi syndrome --

-- Rhythm and LG Chem amend bivamelagon licensing agreement --

-- Five-year term loan facility secured, providing access to up to $750 million --

-- Management to host conference call today at 8:00 a.m. ET --

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the third quarter ended September 30, 2026.

“Rhythm continues to make strong progress in bringing IMCIVREE® (setmelanotide) to patients with acquired hypothalamic obesity (HO), highlighted by continued commercial momentum in the United States. Our commercial launch in Japan represents another important milestone in a market with the potential to become our second largest,” said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals. “The strength of the U.S. launch through two quarters reinforces both the significant unmet need in acquired HO and our opportunity to transform care for patients living with this serious disease.”

Dr. Meeker added, “We are excited about advancing our next-generation MC4R agonists, beginning with bivamelagon. Strong clinical results have reinforced our confidence in its potential across multiple indications, and we look forward to initiating pivotal trials in acquired HO and Prader-Willi syndrome. Our restructured bivamelagon royalty agreement with LG Chem reflects our strong belief in the future potential of the portfolio. With a strong global foundation built on IMCIVREE, bivamelagon entering Phase 3 development and further development planned for RM-718, there is a clear and compelling path to long-term growth and value creation for Rhythm.”

Recent Business and Development Highlights

  • Today, the Company announced it has received more than 700 patient start forms for IMCIVREE for acquired HO from more than 500 prescribers as of September 30, 2026, following approval by the U.S. Food and Drug Administration (FDA) on March 19, 2026;

  • Revenue from global sales of IMCIVREE was $92.1 million for the third quarter of 2026, an increase of 29% on a sequential basis from the second quarter of 2026. The number of patients on reimbursed therapy globally increased by 20% as compared to the second quarter of 2026.

  • U.S.: Revenue of $67.5 million, or 73% of product revenue, was generated in the United States in the third quarter of 2026, an increase of $16.5 million or 32% compared to the second quarter of 2026. The sequential quarter-over- quarter growth in U.S. revenue was driven primarily by increased patient demand for IMCIVREE in acquired HO, as well as continued growth in demand in Bardet-Biedl syndrome (BBS).

  • Ex-U.S.: Revenue of $24.7 million, or 27% of product revenue, was generated outside the United States, a sequential increase of $4.4 million or 22% compared to the second quarter of 2026. The number of reimbursed patients on IMCIVREE continued to increase in the third quarter of 2026;

  • Today, the Company announced that five presentations have been accepted for presentation at ObesityWeek® 2026, taking place November 14-17, 2026. Presentations include:

  • Definition and Diagnostic Criteria for Acquired Hypothalamic Obesity: Global Expert Consensus;

  • Patient-Reported Outcomes From the TRANSCEND Trial in Acquired Hypothalamic Obesity;

  • Efficacy and Safety of Setmelanotide in Acquired Hypothalamic Obesity: Final Phase 3 Trial Results;

  • Two-Year Phase 3 Trial Results of Setmelanotide in Patients With Acquired Hypothalamic Obesity; and

  • Weight Category Improvement Following Setmelanotide in Patients With Acquired Hypothalamic Obesity.

  • On November 2, 2026, the Company announced an amendment to its exclusive license agreement with LG Chem for bivamelagon. Under the terms of the amendment, Rhythm has agreed to pay LG Chem $350 million in fixed payments over four years in order to reduce the low-to-mid single digit royalty in the original agreement to 1% royalty on net product revenue generated by Rhythm’s MC4R portfolio;

  • On November 2, 2026, the Company entered into a five-year term loan facility led by KKR's HealthCare Royalty ("Healthcare Royalty") in partnership with Blackstone Life Sciences, providing access to up to $750 million of capital. In connection with entry into this loan facility the Company entered into an amended and restated Revenue Interest Financing Agreement with Health Care Royalty;

  • On October 13, 2026, the Company announced the commercial launch of IMCIVREE in Japan for patients with acquired HO;

  • On September 22, 2026, the Company announced Health Canada approval of IMCIVREE for weight management in adult and pediatric patients 4 years of age and older with acquired HO;

  • On September 10, 2026, the Company announced the presentation of six abstracts, including three oral presentations and three poster presentations, at the 64th Annual European Society for Paediatric Endocrinology (ESPE) Meeting. Presentations included:

  • Real-world data demonstrating reductions in BMI and hunger for up to 18 months in paediatric patients with acquired HO treated with setmelanotide through France's early-access program;

  • A Phase 3 post-hoc analysis demonstrating improvements across multiple cardiometabolic risk indices with setmelanotide in paediatric patients with acquired HO;

  • Long-term weight outcomes with setmelanotide in paediatric patients with BBS, POMC deficiency and LEPR deficiency; and

  • Additional analyses evaluating metabolic syndrome severity and risk in acquired HO and clinical characteristics associated with BBS.

  • On August 24, 2026, the Company announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved IMCIVREE for patients with acquired HO in Japan;

  • On August 17, 2026, the Company announced the appointment of Manher (“AJ”) Joshi, M.D., as Chief Medical Officer;

  • On August 11, 2026, the Company announced that IMCIVREE received expanded Marketing Authorization in the United Kingdom for the treatment of obesity and control of hunger in patients with acquired HO due to hypothalamic injury or impairment;

Anticipated Upcoming Milestones

Rhythm expects to achieve the following near-term milestones:

  • Complete enrollment in the Phase 1/2, Part D trial evaluating RM-718 in PWS in the second half of 2026;

  • Initiate a pivotal Phase 3 trial evaluating bivamelagon in acquired HO by year-end 2026;

  • Complete enrollment in the setmelanotide substudy in congenital HO in 2027;

  • Begin country-level launches of IMCIVREE for acquired HO in Europe beginning with Germany in 2027; and

  • Initiate 6-month hyperphagia study to evaluate bivamelagon in PWS in 2027, pending alignment with the FDA.

Third Quarter 2026 Financial Results

**Cash Position:**As of September 30, 2026, cash, cash equivalents and short-term investments were approximately $320.9 million, as compared to $388.9 million as of December 31, 2025. Cash, cash equivalents, and short-term investments as of September 30 do not include the $250 million initial draw on the term loan facility or the $70 million payment due to LG Chem under the terms of the amendment to the licensing agreement for bivamelagon.

Revenue: Net product revenues from global sales of IMCIVREE were $92.1 million for the third quarter of 2026, as compared to $51.3 million for the third quarter of 2025.

R&D Expenses: R&D expenses were $52.5 million in the third quarter of 2026, as compared to $46.0 million in the third quarter of 2025. The year-over-year increase was primarily due to an increase in costs in chemistry, manufacturing, and controls (CMC) activity and clinical trial costs, as well as personnel costs, and costs associated with our achievement of a development milestone for our program focused on developing therapies for congenital hyperinsulinism (CHI).

SG&A Expenses: SG&A expenses were $66.8 million for the third quarter of 2026, as compared to $52.4 million for the third quarter of 2025. The year-over-year increase was primarily due to increased personnel costs, including stock-based compensation, related to expanded business operations.

Other income (expense), net: Other expense, net was $(1.5) million for the third quarter of 2026, as compared to other expense, net of $(0.1) million for the third quarter of 2025. The year-over-year increase in other expense, net was primarily due to less interest income earned in the third quarter of 2026 based on decreasing average cash and short-term investments.

Net Loss attributable to common stockholders: Net loss attributable to common stockholders was $(42.4) million for the third quarter of 2026, or a net loss per basic and diluted share of $(0.61), as compared to a net loss attributable to common stockholders of $(54.3) million for the third quarter of 2025, or a net loss per basic and diluted share of $(0.82).

Year to Date 2026 Financial Results:

Revenue: Net product revenues relating to sales of IMCIVREE were $223.5 million for the nine months ended September 30, 2026, as compared to $137.5 million for the nine months ended September 30, 2025.

**R&D Expenses:**R&D expenses were $137.6 million for the nine months ended September 30, 2026, as compared to $125.3 million for the nine months ended September 30, 2025. The increase was primarily due to increases in personnel costs partially offset by decreases in chemistry, manufacturing, and controls (CMC) costs for drug formulation and autoinjector development for RM-718 and a decrease in clinical trial costs.

SG&A Expenses: SG&A expenses were $197.8 million for the nine months ended September 30, 2026, as compared to $137.5 million for the nine months ended September 30, 2025. The increase was primarily due to higher personnel costs, marketing and promotion costs related to the U.S. and Japanese launches of IMCIVREE for acquired HO, and market access and commercial service costs related to our expanding international business operations.

Other income (expense), net: Other income (expense), net was $(4.5) million for the nine months ended September 30, 2026, as compared to $(3.6) million for the nine months ended September 30, 2025. The increase was primarily due to a change in fair value of the embedded derivative of our deferred royalty obligation and an increase in net unrealized loss on foreign currency, and a decrease in interest income earned.

Financial Guidance: For the year ending December 31, 2026, Rhythm anticipates approximately $360 million to $380 million in Non-GAAP Operating Expenses. Non-GAAP Operating Expenses are derived from:

  • GAAP total operating expenses, inclusive of:

  • R&D expenses of approximately $165 million to $175 million;

  • SG&A expenses of approximately $195 million to $205 million; and

  • Excluding stock-based compensation.

Non-GAAP Operating Expenses is defined as GAAP operating expenses excluding stock-based compensation and fixed consideration related to in-licensing and milestone payments (see below under "Non-GAAP Financial Measures" for more details).

Based on its current operating plans, Rhythm expects that its cash, cash equivalents and short-term investments as of September 30, 2026 will be sufficient to fund the Company’s planned operations for at least 24 months.

Conference Call Information Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET today to review its third quarter 2026 financial results and recent business activities. Participants may register for the conference call here. It is recommended that participants join the call ten minutes prior to the scheduled start.

A webcast of the call will also be available under "Events and Presentations" in the Investor Relations section of the Rhythm Pharmaceuticals website at https://ir.rhythmtx.com/. The archived webcast will be available on Rhythm Pharmaceuticals’ website approximately two hours after the conference call and will be available for 30 days following the call.

About Rhythm Pharmaceuticals Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 4 years and older with acquired hypothalamic obesity, adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. The European Commission (EC) has authorized setmelanotide for the treatment of obesity and control of hunger in patients 4 years of age and above with acquired hypothalamic obesity. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.

Setmelanotide Indication In the United States, setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 4 years and older with acquired HO, and in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).

In the European Union and the United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. In the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.

Limitations of Use

Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:

  • Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign

  • Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity

Contraindication

Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.

WARNINGS AND PRECAUTIONS

**Disturbance in Sexual Arousal:**Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.

**Depression and Suicidal Ideation:**Depression, suicidal ideation and depressed mood have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.

**Hypersensitivity Reactions:**Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.

**Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New Melanocytic Nevi:**Generalized or focal increases in skin pigmentation, darkening of pre-existing nevi, development of new melanocytic nevi and increase in size of existing melanocytic nevi have occurred. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions.

**Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants:**IMCIVREE is not approved for use in neonates or infants. Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and low birth weight infants treated with benzyl alcohol preserved drugs.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection.

USE IN SPECIFIC POPULATIONS

Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See section 4.8 of the Summary of Product Characteristics for information on reporting suspected adverse reactions in Europe.

Please see the full Prescribing Information for additional Important Safety Information.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the safety, efficacy, potential benefits of, and clinical design or progress, including enrollment and initiation of our clinical trials and studies, of any of our products or product candidates at any dosage or in any indication, including, setmelanotide, bivamelagon, and RM-718; the use of setmelanotide in patients with acquired HO and the success of our commercial launch; the timing of our country-level launches of IMCIVREE in Europe; our expectations surrounding potential regulatory submissions, progress, or approvals and timing thereof for any of our product candidates; the commercial growth of IMCIVREE; the estimated market size and addressable population for our drug products, including setmelanotide for the treatment of acquired HO and the potential for the market in Japan; the future announcement of data from our ongoing clinical trials, and ongoing enrollment in our clinical trials; existing or future collaboration agreements; the Company’s business strategy and plans; our anticipated financial performance and financial position for any period of time, including our estimated Non-GAAP Operating Expenses for the year ending December 31, 2026; and the sufficiency of our cash, cash equivalents and short-term investments to fund our operations for at least 24 months; and the timing of any of the foregoing. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, risks associated with the laws and regulations governing our international operations and the costs of any related compliance programs, our ability to successfully commercialize setmelanotide, our liquidity and expenses, our ability to retain our key employees and consultants, and to attract, retain and motivate qualified personnel, and general economic conditions, and the other important factors, including those discussed under the caption “Risk Factors” in Rhythm’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this press release or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise.

Non-GAAP Financial Measures This press release includes Non-GAAP Operating Expenses, a supplemental measure of our performance that is not required by, or presented in accordance with, U.S. GAAP and should not be considered as an alternative to operating expenses or any other performance measure derived in accordance with GAAP.

We define Non-GAAP Operating Expenses as GAAP operating expenses excluding stock-based compensation and fixed consideration related to in-licensing and milestone payments.

We caution investors that amounts presented in accordance with our definition of Non-GAAP Operating Expenses may not be comparable to similar measures disclosed by our competitors because not all companies and analysts calculate this non-GAAP financial measure in the same manner. We present this non-GAAP financial measure because we consider it to be an important supplemental measure of our performance and believe it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Management believes that investors’ understanding of our performance is enhanced by including this non-GAAP financial measure as a reasonable basis for comparing our ongoing results of operations.

Management uses this non-GAAP financial measure for planning purposes, including the preparation of our internal annual operating budget and financial projections; to evaluate the performance and effectiveness of our operational strategies; and to evaluate our capacity to expand our business. This non-GAAP financial measure has limitations as an analytical tool, and should not be considered in isolation, or as an alternative to, or a substitute for operating expenses or other financial statement data presented in accordance with GAAP in our consolidated financial statements.

Rhythm has not provided a quantitative reconciliation of forecasted Non-GAAP Operating Expenses to forecasted GAAP operating expenses because the Company is unable, without making unreasonable efforts, to calculate the reconciling item, stock-based compensation expenses, with confidence. This item, which could materially affect the computation of forward-looking GAAP operating expenses, is inherently uncertain and depends on various factors, some of which are outside of Rhythm's control.

Corporate Contact: David Connolly Head of Investor Relations and Corporate Communications Rhythm Pharmaceuticals, Inc. 857-264-4280 [email protected]

| Rhythm Pharmaceuticals, Inc. |

| Condensed Consolidated Statements of Operations and Comprehensive Loss |

| (in thousands, except share and per share data) |

| (Unaudited) |

| |

| | Three months ended September 30, | Nine months ended September 30, |

| | | 2026 | | | | 2025 | | | 2026 | | | | 2025 | |

| Revenues: | | | | | | |

| Product revenue, net | $ | 92,128 | | | $ | 51,298 | | $ | 223,494 | | | $ | 137,518 | |

| License revenue | | — | | | | — | | | — | | | | (5,014 | ) |

| Total revenues | | 92,128 | | | | 51,298 | | | 223,494 | | | | 132,504 | |

| Costs and expenses: | | | | | | |

| Cost of sales | | 12,166 | | | | 5,499 | | | 28,254 | | | | 14,690 | |

| Research and development | | 52,480 | | | | 46,027 | | | 137,634 | | | | 125,307 | |

| Selling, general, and administrative | | 66,752 | | | | 52,425 | | | 197,793 | | | | 137,460 | |

| Total costs and expenses | | 131,398 | | | | 103,951 | | | 363,681 | | | | 277,457 | |

| Loss from operations | | (39,270 | ) | | | (52,653 | ) | | (140,187 | ) | | | (144,953 | ) |

| Other income (expense): | | | | | | |

| Other income (expense), net | | (157 | ) | | | 274 | | | (840 | ) | | | 1,207 | |

| Interest expense | | (4,495 | ) | | | (4,742 | ) | | (13,618 | ) | | | (15,968 | ) |

| Interest income | | 3,163 | | | | 4,328 | | | 9,937 | | | | 11,208 | |

| Total other income (expense), net | | (1489 | ) | | | (140 | ) | | (4,521 | ) | | | (3,553 | ) |

| Loss before income taxes | | (40,759 | ) | | | (52,793 | ) | | (144,708 | ) | | | (148,506 | ) |

| Provision (benefit) for income taxes | | 610 | | | | 111 | | | 1,598 | | | | 528 | |

| Net loss | $ | (41,369 | ) | | $ | (52,904 | ) | $ | (146,306 | ) | | $ | (149,034 | ) |

| Accrued dividends on convertible preferred stock | | (984 | ) | | | (1,375 | ) | | (3,153 | ) | | | (4,046 | ) |

| Net loss attributable to common stockholders | $ | (42,353 | ) | | $ | (54,279 | ) | $ | (149,459 | ) | | $ | (153,080 | ) |

| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.61 | ) | | $ | (0.82 | ) | $ | (2.18 | ) | | $ | (2.38 | ) |

| | | | | | | |

| Weighted-average common shares outstanding, basic and diluted | | 69,046,050 | | | | 66,261,055 | | | 68,541,561 | | | | 64,346,588 | |

| | | | | | | |

| Net loss | $ | (41,369 | ) | | $ | (54,279 | ) | $ | (146,306 | ) | | $ | (153,080 | ) |

| Other comprehensive income (loss): | | | | | | |

| Foreign currency translation adjustment | | 77 | | | | 834 | | | 870 | | | | (1,272 | ) |

| Unrealized gain (loss), net on marketable securities | $ | (909 | ) | | $ | 488 | | $ | (1,818 | ) | | | 385 | |

| Comprehensive loss | $ | (42,201 | ) | | $ | (52,957 | ) | $ | (147,254 | ) | | $ | (153,967 | ) |

| Rhythm Pharmaceuticals, Inc. |

| Condensed Consolidated Balance Sheets |

| (in thousands, except share and per share data) |

| (Unaudited) |

| |

| | September 30, 2026 | | December 31, 2025 |

| | | | |

| Assets | | | |

| Current assets: | | | |

| Cash and cash equivalents | $ | 39,981 | | | $ | 54,301 | |

| Short-term investments | | 280,963 | | | | 334,648 | |

| Accounts receivable, net | | 39,120 | | | | 26,081 | |

| Inventory | | 31,187 | | | | 25,753 | |

| Prepaid expenses and other current assets | | 28,111 | | | | 26,133 | |

| Total current assets | | 419,362 | | | | 466,916 | |

| Property and equipment, net | | 569 | | | | 1,104 | |

| Right-of-use asset | | 2,694 | | | | 3,049 | |

| Intangible assets, net | | 16,678 | | | | 5,319 | |

| Restricted cash | | 1,281 | | | | 522 | |

| Other long-term assets | | 2,548 | | | | 3,286 | |

| Total assets | $ | 443,132 | | | $ | 480,196 | |

| Liabilities, Convertible Preferred Stock and Stockholders’ equity | | | |

| Current liabilities: | | | |

| Accounts payable | $ | 10,687 | | | $ | 13,947 | |

| Accrued expenses and other current liabilities | | 124,721 | | | | 83,855 | |

| Lease liability | | 731 | | | | 650 | |

| Deferred revenue | | — | | | | 194 | |

| Deferred royalty obligation, current | | 14,751 | | | | 7,296 | |

| Total current liabilities | | 150,890 | | | | 105,942 | |

| Long-term liabilities: | | | |

| Deferred royalty obligation | | 87,915 | | | | 100,886 | |

| Lease liability, non-current | | 2,784 | | | | 3,342 | |

| Total liabilities | | 241,589 | | | | 210,170 | |

| Commitments and contingencies (Note 14) | | | |

| Series A convertible preferred stock, $0.001 par value: 150,000 shares authorized; 115,000 and 132,500 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively. Liquidation preference of $116,725 and $132,500 as of September 30, 2026, and December 31, 2025, respectively. | | 113,577 | | | | 130,957 | |

| Stockholders’ equity: | | | |

| Preferred stock, $0.001 par value: 9,850,000 shares authorized; no shares issued and outstanding at September 30, 2026 and December 31, 2025 | | — | | | | — | |

| Common stock, $0.001 par value: 120,000,000 shares authorized; 69,314,825 and 67,205,321 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | | 70 | | | | 67 | |

| Additional paid-in capital | | 1,587,823 | | | | 1,491,675 | |

| Accumulated other comprehensive loss | | (1,744 | ) | | | (796 | ) |

| Accumulated deficit | | (1,498,183 | ) | | | (1,351,877 | ) |

| Total stockholders’ equity | | 87,966 | | | | 139,069 | |

| Total liabilities, convertible preferred stock and stockholders’ equity | $ | 443,132 | | | $ | 480,196 | |

Primary Logo

Source: Rhythm Pharmaceuticals, Inc.

November 2, 2026

PDF Version

-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 --

-- Rhythm to pay LG Chem additional fixed payments totaling $350 million over four years --

-- Rhythm secures $750 million term-loan facility led by KKR’s HealthCare Royalty in partnership with Blackstone to support the amended LG Chem agreement, global commercialization efforts and continued pipeline investment --

BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today announced an amendment to the global exclusive license agreement with LG Chem, Ltd. for bivamelagon, an investigational oral small-molecule melanocortin-4 receptor (MC4R) agonist. The Company also announced a five-year term loan facility led by KKR’s HealthCare Royalty (“HealthCare Royalty”) in partnership with funds managed by Blackstone (“Blackstone”), providing access to up to $750 million of capital.

“MC4R agonism has been shown to achieve a profound impact on patients living with hyperphagia and severe obesity associated with rare MC4R pathway diseases,” said David Meeker, M.D., Chairman, President and Chief Executive Officer of Rhythm. “With its deep scientific expertise, LG Chem succeeded where many failed in developing the first oral MC4R agonist in bivamelagon, which has been shown to achieve clinically meaningful weight loss in patients living with acquired hypothalamic obesity (HO). Our commitment to this program reflects our confidence in bivamelagon’s potential to deliver meaningful benefits for patients and create substantial long-term value for shareholders.”

“This amendment reflects the strong confidence both companies have in the value and potential of bivamelagon,” said Jeewoong Son, President of LG Chem Life Sciences Company. “By expanding global development efforts, we hope to accelerate patient access to an innovative treatment option for rare obesity diseases.”

Bivamelagon Licensing Agreement In January 2024, Rhythm entered into a global licensing agreement with LG Chem for exclusive worldwide rights to develop and commercialize bivamelagon, then known as LB54640. Under the original agreement, Rhythm paid LG Chem a total of $80 million in cash and $20 million in Rhythm common stock and agreed to potential regulatory and sales milestone payments of up to $205 million, as well as commercial sales royalties of low-to-mid-single digits on global net sales of products within Rhythm’s MC4R portfolio, dependent upon the number of indications approved by regulatory authorities.

Under the terms of the amended agreement, Rhythm will make additional fixed payments totaling $350 million to LG Chem in four installments: $70 million within 15 business days following the effective date of the Amendment, which is Nov. 2, 2026; $100 million in September 2027; $100 million in September 2028; and $80 million in September 2029. In addition, the variable royalty structure in the original agreement will be replaced with a 1% royalty on global net sales of products within Rhythm’s MC4R portfolio, beginning on January 1, 2029, or upon the first commercial sale of bivamelagon, if earlier.

With LG Chem's agreement, Rhythm may satisfy certain of the foregoing fixed payment obligations through additional royalties.

In addition to potential development, regulatory and commercial milestone payments totaling up to $205 million in the original agreement, the amendment includes an additional milestone payment of up to $200 million based on achievement of $3 billion in annual global net sales of its MC4R portfolio.

Term Loan Facility Highlights: Today, Rhythm also announced that it has entered into a $750 million term-loan facility, with $500 million committed, led by KKR’s HealthCare Royalty in partnership with Blackstone, to support the amended licensing agreement with LG Chem as well as ongoing global commercialization efforts and R&D programs.

The five-year term loan facility includes an initial $250 million draw at closing, which is expected to occur on November 6, 2026, subject to the satisfaction of customary closing conditions, and up to $250 million of additional committed capital through June 30, 2028 at Rhythm’s option, in three delayed-draw tranches consisting of two tranches of $100 million and one tranche of $50 million. In addition, Rhythm has access to an additional $250 million by mutual agreement. Borrowings under the facility will bear interest at the Secured Overnight Financing Rate, or SOFR, plus 4.60%. The five-year loan has no scheduled principal amortization prior to maturity and no equity component. The facility includes customary prepayment premiums that decline over the term of the loan.

In connection with the term loan, Rhythm and HealthCare Royalty have agreed to amend the Company’s existing revenue interest financing agreement, with the amendment expected to become effective upon the closing of the term loan. The amendments remove the debt-like covenants and default provisions, limit the collateral securing the agreement and modify the agreement’s material adverse effect provisions.

“We value our partnership with HealthCare Royalty and welcome our new partnership with Blackstone. We believe the mutually beneficial terms of this financing agreement enhance our financial flexibility while positioning us to create meaningful long-term shareholder value,” said Hunter C. Smith, Chief Financial Officer of Rhythm.

“Rhythm has established a clear leadership position in MC4R pathway diseases, supported by a growing commercial foundation and a differentiated pipeline spanning multiple potential indications,” said Clarke B. Futch, Chairman and Chief Executive Officer of HealthCare Royalty.

M. Craig Shepherd, Senior Managing Director, Blackstone, added, “We are pleased to partner with Rhythm and HealthCare Royalty through a financing structure that supports the Company’s long-term strategy and reflects our shared confidence in the value and potential of its MC4R portfolio.”

J. Wood Capital Advisors served as financial advisor to Rhythm in connection with the financing.

About Rhythm Pharmaceuticals Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 4 years and older with acquired hypothalamic obesity, adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and control of hunger in patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment; and for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.

About LG Chem LG Chem is a leading global chemical company with a diversified business portfolio spanning across petrochemicals, advanced materials, and life sciences. LG Chem Life Sciences, the life sciences business division of LG Chem, is dedicated to developing and delivering innovative medicines across a broad range of therapeutic areas. Guided by its mission to transform people’s lives through inspiring science and leading innovation, LG Chem Life Sciences is offering differentiated solutions to its customers. For more information, please visit www.lgchem.com.

About HealthCare Royalty, a business of KKR HealthCare Royalty is a leading royalty acquisition company founded in 2006 that is majority owned by KKR & Co. Inc. (NYSE: KKR). Over two decades, the HealthCare Royalty team has developed a strong track record of investing in commercial-stage and near-commercial-stage biopharmaceutical assets, committing $8+ billion in over 110 biopharmaceutical products. With offices in New York, San Francisco, Boston, London and Miami, HealthCare Royalty continues to advance biopharmaceutical innovation by providing innovative capital solutions to counterparties. For more information, visit https://www.hcrx.com. HEALTHCARE ROYALTY® and HCRx® are registered trademarks of HealthCare Royalty Management, LLC.

About Blackstone Blackstone is the world’s largest alternative asset manager. Blackstone seeks to deliver compelling returns for institutional and individual investors by strengthening the companies in which the firm invests. Blackstone’s nearly $1.4 trillion in assets under management include global investment strategies focused on real estate, private equity, credit, infrastructure, life sciences, growth equity, secondaries and hedge funds. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, X (Twitter), and Instagram.

Setmelanotide Indication In the United States, setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity, in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).

In the European Union and the United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above, and for the treatment of obesity and control of hunger in adults and children 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment. In the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician experienced in the diagnosis and management of rare forms of obesity with genetic or hypothalamic origin.

Limitations of Use

Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:

  • Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign

  • Other types of obesity not related to acquired HO, BBS, or POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity.

Important Safety Information

CONTRAINDICATIONS

Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.

WARNINGS AND PRECAUTIONS

**Disturbance in Sexual Arousal:**Spontaneous penile erections and increased frequency of penile erections in males have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.

**Depression and Suicidal Ideation:**Depression and suicidal ideation have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.

**Hypersensitivity Reactions:**Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.

**Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New Melanocytic Nevi:**Generalized or focal increases in skin pigmentation occurred in the majority of IMCIVREE-treated patients. IMCIVREE may also cause development of new melanocytic nevi or darkening of pre-existing nevi. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions.

**Acute Adrenal Insufficiency with Acquired HO:**Patients with acquired HO and secondary adrenal insufficiency reported serious adverse reactions related to acute adrenal insufficiency in 5% of IMCIVREE-treated patients and no placebo-treated patients. In patients with secondary adrenal insufficiency, monitor for clinical signs of acute adrenal insufficiency.

Sodium Imbalance in Patients with Acquired HO and Central Diabetes Insipidus: Patients with acquired HO and concomitant central diabetes insipidus (DI)/arginine vasopressin (AVP) deficiency reported hyponatremia in 6% of IMCIVREE-treated patients and 2% of placebo-treated patients and hypernatremia in 5% of IMCIVREE-treated patients and 4% of placebo-treated patients. Monitor serum sodium levels with changes in fluid intake and hydration status. Adjust the doses of concomitant therapies for DI/AVP deficiency as needed.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥20% in at least 1 indication) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection.

USE IN SPECIFIC POPULATIONS

Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. See section 4.8 of the Summary of Product Characteristics for information on reporting suspected adverse reactions in Europe.

Please see the full Prescribing Information for additional Important Safety Information.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the safety, efficacy, potential benefits of, and clinical design or progress of any of our products or product candidates at any dosage or in any indication, including, setmelanotide, bivamelagon, and RM-718; our continued collaboration with LG Chem; the anticipated benefits of the term loan; the expected timing of the closing and initial funding of the term loan and the effectiveness of the amendment to our revenue interest financing agreement; the estimated market size and addressable population for our drug products, including setmelanotide for the treatment of acquired HO; and the timing of any of the foregoing. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, the satisfaction of the conditions to closing of the term loan, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, risks associated with the laws and regulations governing our international operations and the costs of any related compliance programs, our ability to successfully commercialize setmelanotide, our liquidity and expenses, our ability to retain our key employees and consultants, and to attract, retain and motivate qualified personnel, and general economic conditions, and the other important factors, including those discussed under the caption “Risk Factors” in Rhythm’s Quarterly Report on Form 10-Q for the three months ended June 30, 2026, and in Rhythm’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the Securities and Exchange Commission (the “SEC”) and our other filings with the SEC. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Corporate Contacts: David Connolly Head of Investor Relations and Corporate Communications Rhythm Pharmaceuticals, Inc. 857-264-4280 [email protected]

Kate Walsh Director, Corporate Communications Rhythm Pharmaceuticals, Inc. (857) 264-4280 [email protected]

Primary Logo

Prompts

Rhythm Pharmaceuticals, Inc. (ticker RYTM), listed in United States.

Company History

Date Change Detail
Oct 13, 2015 Renamed RHYTHM METABOLIC, INC. → RHYTHM PHARMACEUTICALS, INC.

ETFs Holding Rhythm Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
MEDI 3.10% 12,452 $ 1.368M Nov 12, 2026
FSML 1.03% 11,653 $ 1.294M Jun 30, 2026
GSC 0.75% 19,815 $ 2.103M Aug 31, 2026
GDOC 0.73% 1,346 $ 142.851K Aug 31, 2026
SCDS 0.66% 515 $ 60.054K Nov 17, 2026
MSSM 0.46% 30,824 $ 3.271M Aug 31, 2026
HELX 0.42% 1,048 $ 116.359K Jun 30, 2026
FSEG 0.41% 213 $ 23.649K Jun 30, 2026
FSCC 0.37% 12,742 $ 1.352M Aug 31, 2026
RUSC 0.27% 1,895 $ 210.402K Jun 30, 2026
FTKI 0.26% 620 $ 66.638K Nov 16, 2026
JGRO 0.26% 199,557 $ 23.27M Nov 17, 2026
RESM 0.23% 77 $ 8,549.31 Jun 30, 2026
FESM 0.21% 106,949 $ 11.875M Jun 30, 2026
TMSL 0.19% 46,960 $ 5.214M Jun 30, 2026
CLSE short -0.16% -13,510 $ -1.434M Aug 31, 2026
IALT 0.02% 15,353 $ 1.65M Nov 16, 2026
JSTC 0.02% 684 $ 73.516K Nov 17, 2026